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Abstract Twin and family studies in autistic disorders
(AD) have elucidated a high heritability of AD. In this
literature review, we will present an overview on molecular
genetic studies in AD and highlight the most recent ﬁnd-
ings of an increased rate of copy number variations in AD.
An extensive literature search in the PubMed database was
performed to obtain English published articles on genetic
ﬁndings in autism. Results of linkage, (genome wide)
association and cytogenetic studies are presented, and
putative aetiopathological pathways are discussed. Impli-
cations of the different genetic ﬁndings for genetic coun-
selling and genetic testing at present will be described. The
article ends with a prospectus on future directions.
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Introduction
Autistic disorders (AD) are a group of disorders charac-
terised by the three core problem areas: qualitative
impairment in social interaction and communication, and
restricted repetitive and stereotyped patterns of behaviour,
interests, and activities [88]. The three disorders autism,
Asperger syndrome (AS) and pervasive developmental
disorder-not otherwise speciﬁed (PDD-NOS) are currently
conceptualised by most researchers as a continuum of the
same disorder with varying degrees of severity, associated
intellectual functioning and medical conditions, possibly
also including the broader autism phenotype (BAP) [80].
Recent studies estimated the prevalence of AD to around
0.5–1% [5, 17]. AD are predominantly genetically deter-
mined disorders with a heritability of around 90% [29].
Non-genetic medical conditions (phenocopies) are rare,
however, they are especially relevant with regard to the
prevention of AD. Retrospective case series clearly indi-
cate maternal valproic acid use [87] during pregnancy as
risk factor. The association of congenital rubella with
autism has been studied in a longitudinal study on 243
children with congenital rubella of whom 7% developed
typical or atypical autism [18]. With about 2%, another
relatively frequent medical condition in AD is cerebral
palsy [28].
The ﬁndings of cytogenetic abnormalities and single
gene disorders associated with AD indicate genetic heter-
ogeneity and different modes of inheritance in individual
families. For idiopathic AD, i.e. cases with unknown
genetic or environmental cause, oligogenic, polygenic, and
multifactorial mechanisms have additionally been pro-
posed. Some evidence points to a different genetic model
in simplex versus multiplex AD cases [93]. Previously,
hypothesis free genome wide linkage approaches were
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and candidate gene association studies attempted to eluci-
date rare or common variants associated with the disorder.
Owing to technical advances in CHIP based technology
and cytogenetics, recent studies have focussed on hypoth-
eses free genome wide association (GWA) and copy
number variation (CNV) studies.
In this review on molecular genetic ﬁndings in AD, we
summarise ﬁndings of a previous review article on the
genetics of AD [29] and add ﬁndings from recent studies
(2007–2009). For both articles, a systematic search on
molecular genetic studies in AD was performed using the
database PubMed and adding information from reference
lists of published articles. The following key words were
used: ‘‘autistic disorder’’, ‘‘autism spectrum disorder’’,
‘‘autism’’, ‘‘Asperger Syndrome’’ in combination with
‘‘genetic’’, ‘‘gene’’, ‘‘linkage’’, ‘‘association’’, ‘‘copy
number variation’’, ‘‘genome wide’’, ‘‘cytogenetic’’,
‘‘duplication’’, ‘‘deletion’’, ‘‘translocation’’. Results of
association studies were only reported if at least one rep-
lication of another or the same variant in the speciﬁc gene
was published. For a graphical overview on the reported
replicated ﬁndings, compare Fig. 1.
Linkage studies
Linkage studies aim to elicit gene loci by mapping genes
in families. Linkage can be deﬁned as the tendency for
alleles close together on the same chromosome to be
transmitted together, as an intact unit, through meiosis.
Linkage studies are either performed as full genome
screens with a dense set of genetic markers covering all
chromosomes, or locally (ﬁne-mapping) at a certain
chromosomal area of interest. Linkage has been found in
at least two independent studies in regions 2q21–33,
3q25–27, 3p25, 4q32, 6q14–21, 7q22, 7q31–36, 11p12–
13, 17q11–21 [2, 24, 29, 50, 60, 74]. A meta-analysis
conﬁrmed the region 7q22–32, and reported suggestive
evidence for linkage to 10p12–q11.1 and 17p11.2–q12
[75]. Due to the rarity of the disorder, genome scans often
were ﬁrst performed in a smaller set of families and again
in an enlarged set of families, containing the previously
assessed families as well. This, however, did not always
result in more pronounced linkage ﬁndings at previously
described loci, but more often in diminished LOD scores.
This might be due to different loci containing risk genes
in different populations, to false positive or negative
ﬁndings due to differing linkage disequilibrium patterns in
different populations, towards the involvement of risk
alleles of small effect, which are not detected by linkage
studies, and again towards heterogeneity of AD.
Single gene disorders and ﬁndings of association studies
Co-occurrence of AD and single gene disorders has been
observed for a long time. The most prevalent single gene
disorders in AD are tuberous sclerosis (TSC1/TSC2;
around 1%) and fragile X syndrome (around 3–5%). More
rare ( 1%), but medically treatable single gene disorders
are phenylketonuria (PKU) and Smith–Lemli–Opitz (SLO)
syndrome caused by mutations in 7-dehydrocholesterol
reductase (DHCR7) [4, 29, 66]. The rate of AD in these
disorders also is increased, but AD is not observed in all
individuals carrying the mutation: fragile-X-syndrome ca.
25% (males), tuberous sclerosis ca. 20%; SLO ca. 50%;
PKU ca. 10% [1]. Mutation screening and subsequent
association studies have elucidated other rare causes of
(most likely) single gene disorders in individuals with AD.
Additionally, several common variants in genes located in
linked regions were assessed for association with AD. In
Fig. 1 Replicated ﬁndings of linkage (red bars), Genome wide
association (yellow bars), copy number variation (green bars) and
candidate gene (blue bars) studies as discussed in the text
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ings will be presented.
Chromosome 2
Different common variants in the mitochondrial aspartate/
glutamate carrier (SLC25A12) gene located on 2q24 were
associated with AD in several studies [29, 67].
Chromosome 3
Oxytocin plays a crucial role in social cognition and
behaviour [22] and the oxytocin receptor gene (OXTR)i s
located under the linkage peak on 3p24-26. Several single
nucleotide polymorphism (SNP) alleles and haplotypes of
OXTR were associated with AD [40, 46, 89].
Chromosome 4
One association study and a cytogenetic ﬁnding point
towards the possible involvement of GABA-A receptor
subunit genes encoded on chromosome 4p12 [29, 79]. In
addition, a gene expression study observed down-regula-
tion of several GABA-A-receptor subunits in the parietal
cortex of individuals with autism [25]. No association
studies were performed to date on genes at the 4q32 locus.
Chromosome 6
Three studies found evidence for association of different
SNP genotypes or alleles in the Glutamate receptor 6
(GluR6)gene underthelinkage peakonchromosome6[29].
Chromosome 7
Most candidate genes assessed in AD are located on
chromosome 7q22-36, as this area is best replicated from
linkage studies. Mutations or variants in the following
candidate genes could not clearly be replicated as risk
factors for AD [29]: FOXP2 (a gene which was mutated in
a severe monogenic form of speech and language impair-
ment in one family) [27], RELN (neuronal migration, for-
mation of cortical layers, synaptogenesis), PTPRZ1 (highly
expressed during embryogenesis), NRCAM, WNT2, and
HOXA1 (hindbrain development in mouse).
TheRELN(Reelin)genecodesforasignallingproteinthat
plays a crucial role in neuronal migration, formation of cor-
tical layers and synaptogenesis. Three studies supported the
involvement of a trinucleotide repeat polymorphism in the
50UTRregioninReelininAD[58,64,69],whereasﬁveother,
at least similarly powered, studies did not [9, 21, 44, 47, 92].
Differentrareandcommon,possiblyfunctionalvariantsin
LAMB1 were associated with AD in two studies [10, 29, 38].
LAMB1 encodes the b1 chain of laminin, which is an
important glycoprotein promoting neuronal migration and
neurite outgrowth in the developing nervous system.
Different alleles of two SNPs in the Engrailed 2 (EN2)-
gene on chromosome 7q36 were associated with AD in
several independent samples [11, 29, 84, 90]. EN2 is a
homeobox transcription factor, which plays a role during
the development of cerebellar and brainstem functions.
Common variants as well as rare mutations in the
contactin-associated protein-like 2 (CNTNAP2), a member
of the neurexin superfamily involved in cell-adhesion and
neuronal migration [2, 3, 6] also increased the risk for AD
in several independent samples. Gene-expression analyses
in the developing human brain identiﬁed CNTNAP2 as
enriched in circuits important for language development.
The gene encoding the pleiotropic MET receptor tyro-
sine kinase plays a role in brain development and gastro-
intestinal repair. As some individuals with AD suffer from
gastrointestinal symptoms (GIS), this gene was speciﬁcally
assessed in individuals with AD and GIS. A functional
promotor variant, several other SNP genotypes or alleles as
well as rare mutations were associated with AD in several
independent samples, predominantly in individuals with
GIS [14, 16, 71]. In a post-mortem brain protein-expression
analysis, AD individuals showed lower levels of the MET
protein compared to controls [15].
Chromosome 10
PTEN (phosphatase and tensin homologue, located on
10q23.3) is a tumour suppressor gene that acts as a negative
regulator in the PI3-kinase (PI3K) pathway. Heterozygous
PTEN mutations were identiﬁed in a subset of individuals
with autism, macrocephaly and/or developmental delay
[13, 35, 78], thus rendering affected individuals PTEN-
haploinsufﬁcient.
Chromosome 15
Several variants of genes on 15q11-13 were assessed as
risk factors, as cytogenetic abnormalities of this region are
frequently observed in AD (see below). In candidate gene
association studies to date, inconclusive ﬁndings were
reported with regard to ATP10C, UBE3A and the gamma-
aminobutyric acid (GABA) receptor genes located on 15q
[29].
Chromosome 17
Due to ﬁndings of platelet hyperserotonemia in children
with autism and their ﬁrst-degree relatives, common vari-
ants in the Serotonin-transporter gene (SLC6A4) were
assessed by several studies [29]. A recent meta-analysis,
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alleles on AD risk [37].
Chromosome 22
Several case reports indicated 22q13.3 deletions and
duplications as risk factors for AD. Therefore, SHANK3,
the gene encoding a synaptic scaffolding protein, was
assessed for mutations and common variants possibly
associated with AD. Several studies observed rare muta-
tions in individuals with AD, occurring most often de
novo, but also inherited from (unaffected) parents. Similar
to reports of mutations of X-chromosomal genes (see
below), SHANK3 mutations might cause a monogenic
form of non-verbal or severely speech delayed AD [23,
30, 56]. The frequency of SHANK3 mutations was esti-
mated to 0.5–1% in AD individuals. Common variants
were not detected as risk factors [73]. A recent study,
however, also has reported SHANK3 deletions in healthy
individuals [31].
X-chromosome
Despite rare positive linkage ﬁndings for loci on the X-
chromosome, several variants in genes on the X-chro-
mosome were assessed for association with AD, as the
sex distribution in AD is markedly skewed (male:female
= 4:1). Two neuroligin genes on Xq13 and Xp22 were
screened for mutations in several studies. Neuroligins are
essential components of synaptogenesis. Despite the
ﬁndings of several non-conservative mutations in single
families in NLGN3 and NLGN4 these could not be rep-
licated in larger samples of individuals with AD [29].
Similarly, two mutations identiﬁed in the ribosomal pro-
tein gene RPL10 on Xq28 were not replicated in a sub-
sequent study [32, 43].
MeCP2-mutations are risk factors for Rett-Syndrome,
which by some authors is regarded as an AD, but clearly
differs phenotypically from AD by deterioration of motor
abilities and very low IQ. In addition, in males with mental
retardation and progressive spasticity, duplications of the
MECP2 region were repeatedly observed [48]. In AD
samples in contrast, no association of MeCP2 variants was
found [29].
Y-chromosome
There are only a few studies, which have investigated
variants of Y chromosomal genes in autism. A recent study
reported nominal association with a SNP variant in
NLGN4Y [63] in contrast to previous ﬁndings [42, 91].
Thus, an inﬂuence of genes on the Y chromosome has not
been established to date.
Genome wide association studies
The above reported candidate gene association studies are
based on speciﬁc hypotheses. Results in one sample often
were not replicated in subsequent samples, possibly indi-
cating false positive reports. Other causes might be heter-
ogeneity across populations, bias due to technical artefacts,
population stratiﬁcation or environmental modiﬁers. False
negative reports, especially in light of genes of small effect,
hamper further understanding of genetic mechanisms in
autism. Similar to linkage studies, genome wide associa-
tion (GWA) studies are considered hypothesis-free studies.
Performing a GWA study in a sufﬁciently large sample and
replicating the most signiﬁcant SNPs in an independent
sample with sufﬁcient power is currently considered as a
design avoiding the report of false positive ﬁndings [70].
However, GWA studies to date did not replicate any of the
previous linkage or association ﬁndings, most likely due to
the same reasons as the non-replication of hypotheses
based association studies. In addition, the ‘‘common dis-
ease–common variant’’ genetic model underlying GWA
studies might not hold true for the majority of AS cases
[51]. GWA studies done on currently available samples and
with the currently available SNP assays cannot detect risk
alleles with low minor allele frequency or rare variants
which might be relevant in the aetiology of AD [53]. To
date, three GWA studies were performed in AD [49, 83,
85]. Common genetic variants on 5p14.1 and 5p15 were
replicated in two independent samples, respectively, each
carrying a small increased risk (OR 1.2) or protective effect
(OR 0.6) [83, 85].
At 5p14.1 segments with a high degree of evolutionary
conservation can be found, suggesting potential regulatory
function. Genes CDH9 and CDH10 are near the two rep-
licated SNPs [83]. These genes encode cadherins, which
are a group of proteins that are involved in calcium-
dependent cell–cell junctions in the nervous system,
thereby shaping the physical structure and functional con-
nectivity of the brain. The one replicated SNP at 5p15 is
located near TAS2R1, a gene encoding a bitter taste
receptor, and the semaphorin 5A gene (SEMA5A) impli-
cated in axonal guidance. SEMA5A was downregulated in
lymphoblastoid cell lines as well as occipital lobe cortex in
AD [85].
Chromosomal abnormalities
For a long time suspected causes of heterogeneity in AD are
chromosomal abnormalities which can be observed by
standard karyotyping. Numerous case reports of chromo-
somal abnormalities on almost each single chromosome in
AD do exist [82], however, epidemiological data are
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are the lack of standardised assessment methods for AD, the
inclusion of subjects with autistic features but no clear AD
diagnosis, and the lack of standardised assessment of cog-
nitive and adaptive functioning. Recent studies estimated a
rate of 3–5% of cytogenetic abnormalities in AD [59]. Some
studies aimed to elicit candidate genes or candidate gene
regions by a detailed analysis of the boundaries of the
cytogenetic abnormalities found in AD [82].
With a rate of approximately 1%, the most prevalent
cytogenetic abnormalities are observed on chromosome
15q11-13 [20, 29], in most cases maternally, but also
paternally inherited duplications. Further relatively frequent
ﬁndings are deletions of chromosome 2q37, chromosome
7q31 and deletions or duplications of chromosome 22q13.
In addition, Klinefelter Syndrome (XXY) as well as dupli-
cations of the Williams–Beuren–Syndrome region 7q11.23
and deletions of 22q11 (Velo-cardio-facial Syndrome) are
associated with increased autistic traits [8, 77, 81].
Due to autistic traits in several chromosomal aneuploi-
dies, a cytogenetic evaluation has to be recommended in all
subjects with AD. Some studies reported higher rates of
deletions, duplications or translocations in AD individuals
with mental retardation, abnormal EEG patterns or sei-
zures, muscular hypotonia, severe motor and gait problems,
or dysmorphic features [41], however, chromosomal
anomalies are also observed in individuals without dys-
morphic features [82]. The ﬁnding of a chromosomal
anomaly as a likely cause of AD has strong implications for
genetic counselling and in some cases, like Klinefelter or
Velo-cardio-facial Syndrome, also for the treatment of
other medical conditions associated with the respective
syndrome.
Submicroscopic copy number variations
Due to technological advances, it is now possible to also
assess small cytogenetic abnormalities not detected by
standard karyotyping [34]. Until recently, it was thought
that only 0.1% base pair changes accounted for major
genetic variation between individuals. With the advance of
micro-array-based comparative genomic hybridization
(array-CGH), this view has been challenged by studies that
showed that the genomes of unrelated healthy individuals
vary signiﬁcantly with respect to the number of copies an
individual has of each DNA segment [39, 62]. A copy
number variation (CNV) is currently deﬁned as a DNA
segment longer than 1 kb, with a variable copy number
compared to a reference genome [26]. A CNV can be a
deletion, insertion, duplication or a complex multi-site
variant. It can be inherited or may arise de novo on a
paternally or maternally inherited chromosome. To be
pathogenic, a CNV must affect a gene in a molecular
pathway important in the development or maintenance of
the human body. CNVs might change the transcription rate
of a gene product by increased or decreased transcription,
in case of deletions, they may unmask recessive mutations,
or they might change the coding sequence of a gene.
Recent publications show that some CNVs are observed
more frequently in AD patients compared to control sub-
jects [12, 31, 45, 52, 55, 61, 86]. Similar to the cytogenetic
ﬁndings obtained by standard karyotyping, most CNVs
represent rare, unique events rather than representing
recurrent deletions or duplications. Replicated CNVs from
genome wide studies, which were observed more fre-
quently in AD compared to control individuals, are located
on the following chromosomes: 1q21, 2p16.3 (NRXN1),
3p25-26 (CNTN4), 7q36.2 (DPP6), 15q11-13 (UBE3A,
OR4M2, OR4N4); 16p11.2 (MAPK3, MAZ, DOC2A,
SEZ6L2, HIRIP3, IL6); 22q11.2. Some of these CNV were
observed also more frequently in individuals with mental
retardation or schizophrenia than in controls. ASD speciﬁc
CNVs were not exclusively observed in AD individuals
with speciﬁc dysmorphic features or mental retardation but
were also present in high-functioning patients with autism
with only minor dysmorphology [76].
Summary on genetic mechanisms and possible
functional pathways involved in AD
Molecular genetic studies in AD have come a long way
from the early linkage studies, which aimed at describing a
few loci and subsequently ﬁnding one or a few genes of
major effect relevant for all cases of AD. It has now
become clear, that AD are heterogeneous disorders, caused
by several rare—most likely—monogenetic disorders (as
fragile X syndrome, mutations in TSC1/TSC2, LAMB1,
CNTNAP2, PTEN, DHCR7, SHANK3, NLGN3/4,o r
RPL10). In addition, ‘‘contiguous gene syndromes’’ are
likely causes of AD, as the overall rate of CNVs and large
chromosomal deletions, duplications, and translocations is
increased in individuals with AD compared to controls.
Common variants, on the other hand, may shape the
phenotype or eventually may lead to the disorder by
interacting with rare mutations or CNVs. A mechanism like
this has been shown for PTEN haploinsufﬁcient individu-
als. The serotonin-transporter gene SLC6A4 has been dis-
cussed as both an AD susceptibility gene and a second-site
modiﬁer in AD [7, 36]. A study in PTEN haploinsufﬁcient
mice [57] demonstrated that the phenotypes of these mice
were modiﬁed in an additive fashion by SLC6A4 haploin-
sufﬁciency. In addition, the role of PTEN in the mainte-
nance of genomic stability [65, 72] makes it likely that
PTEN haploinsufﬁciency may increase the probability of a
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tion in a chromosomal region relevant to AD. Common
variants also might increase the risk for autistic traits in the
general population as well as for less severe autistic dis-
orders as Asperger Syndrome or PDD-NOS.
From results of current genetic ﬁndings in AD, it is
likely that mutations or common variants in genes coding
for gene products involved in (1) cell–cell interaction and
synaptic function, including development of dendritic
spines, (2) neuronal migration and growth, or (3) excitatory
and inhibitory neurotransmission are causes of AD. The
pathway inﬂuencing cell–cell interaction and synaptic
function includes NRXNs, NLNGs, CNTN3/4, CNTNAP2,
and SHANK3. In addition, the FMR protein, which is
missing in fragile X syndrome, modulates dendritic spine
formation and synaptic plasticity by inhibiting mGluR1/5
mediated dendritic protein synthesis [33]. Neuronal
migration and growth are inﬂuenced by gene products of
LAMB1, EN2 or the MET receptor tyrosine kinase gene.
The mTor/PI3-kinase (PI3K) pathway involves PTEN,
TSC1/2, and several other genes, which were observed in
CNVs in individuals with AD [19]. It strongly inﬂuences
(neuronal) cell growth. Gene products inﬂuencing the
regulation of excitatory and inhibitory neurotransmission
are GABA and glutamate receptors. In addition, dysbal-
ance of excitatory and inhibitory neurotransmission was
also observed in fragile X syndrome. Clearly, this list of
possibly involved pathways is not exhaustive, and other
mechanisms or pathways may emerge as results of further
studies will be published.
Implications for genetic counselling
Genetic counselling for AD is challenging, as phenotype
and genetic mechanisms are complex. There is a strong
need to carefully assess the children and their family, and
to exclude all known medical causes of the disorder. The
aim of genetic counselling is to provide information to
parents and children, and to estimate the recurrence risk of
the disorder. Genetic counselling further is concerned with
providing psychologically oriented counselling to help
individuals to adapt and adjust to the impact and implica-
tions of the disorder in the family. With regard to AD,
families as a rule wish to know the recurrence risk of the
disorder. From the results of family studies, a sibling
recurrence risk of around 5% (2–8%) can be estimated for
‘‘idiopathic’’ AD not caused by any of the currently known
mechanisms [68]. If a known genetic cause of the disorder
is established, however, a very different recurrence risk
might be present in the individual family. For dominant
single gene disorders with full penetrance, like TSC1/2-
mutations, a sibling recurrence risk of 50% is present, if
one of the parents carries the disease-causing variant, i.e. if
the variant is not a de-novo mutation. In case of recessive
single gene disorders, like Smith–Lemli–Opitz syndrome,
the sibling recurrence risk is 25%. If a child suffers from
fragile X syndrome, the recurrence risk in a brother is up to
50%, and a sister will become a carrier in up to 50% or
might be mildly affected. On the other hand, in the pres-
ence of cytogenetic abnormalities like a chromosome
15q11-13 duplication or duplicated inversion, the recur-
rence risk can be similar to the population prevalence, as
most duplications and inversions arise de-novo during
meiosis. The same is true for CNVs. However, they also
can be inherited, which will result in an entirely different
recurrence risk.
The limited clinical validity of genetic testing for autism
and the related ethical concerns have been delineated in
detail [54]. It seems of particular relevance to keep in mind
the complex genetics and uncertainty principle as well as
the right of the individual and the family not to participate
in genetic testing. Despite contrasting information to
patients, no genetic test does exist to date, by which an AD
can be diagnosed. It remains a diagnosis based on behav-
ioural observation.
Future directions
Due to technical advances, sequencing of the genome will
be available and feasible in the near future. Similar to
results of genome-wide CNV and association studies, the
detection of new mutations, rare and common variants in
cases as well as controls will make it difﬁcult to prove the
relevance of the ﬁndings for AD in general as well as for
the affected individual speciﬁcally. Researchers are faced
with genetic heterogeneity, reduced penetrance, unmasking
of recessive alleles, ‘‘second hit’’ mechanisms, pleiotropy,
epigenetic mechanisms, and possible environmental
mediators. It therefore is of crucial relevance to include on
the one hand more differentiated phenotypic measures, on
the other hand functional aspects on the cellular and
molecular level as well as biological network analysis
approaches to focus on the most relevant ﬁndings. This
approach will need large and thoroughly diagnosed sam-
ples with AD. In parallel, knowledge about population
wide variation at the genomic level in comparison with
phenotypic expression of AD symptoms will add infor-
mation towards involved functional pathways. The ﬁnal
goal anticipated is the development of therapeutic targets
for drug treatments. The development of a molecular
genetic test kit to assist in AD diagnosis might also be
achieved. At the current stage of research, however, a
genetic test does not seem feasible nor ethical due to the
heterogeneity of the disorder, the lack of population-based
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and speciﬁcity analyses in comparison to other psychiatric
or neurological disorders in childhood.
Conclusions
Despite the high-heritability estimates for AD, no major
gene has been observed to be relevant for the majority of
AD diagnoses. In contrast, rare mutations of larger effect
and a few common variants of small effect in several dif-
ferent genes, which are also involved in different cellular
pathways, seem to be causal for many cases of AD. From a
statistical point of view therefore, large AD and control
samples are necessary, to prove the causality of speciﬁc
rare mutations (including CNVs) or variants of small effect
as risk factors for AD. As the disorder shows a high-phe-
notypic variability and additional genetic heterogeneity, it
is of crucial importance to (1) deﬁne clear phenotypes
especially with regard to the broader spectrum of AD and
to the differential diagnosis of other pervasive develop-
mental disorders like Rett syndrome, and (2) to perform a
detailed cytogenetic analysis in every individual with AD
and additional testing for fragile X syndrome in individuals
with AD and low intelligence/mental retardation in clinical
and research settings. It also might be feasible in the near
future, to employ kits assessing the most prevalent cyto-
genetic ﬁndings in individuals with AD. In addition, sam-
ples with mental retardation or other psychiatric disorders,
like schizophrenia, should be compared to elicit the most
speciﬁc risk factors for AD. New technologies, such as
more sophisticated chip based arrays as well as large scale
sequencing will lead to new results which need to be
integrated into meaningful biological models.
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